Article Text

Download PDFPDF

629 Neoadjuvant nivolumab combined with CCR2/5 inhibitor or anti-IL-8 antibody in non-small cell lung cancer and hepatocellular carcinoma
  1. Nicholas Venturini1,
  2. Thomas Marron1,
  3. Maria Casanova-Acebes2,
  4. John Mandeli1,
  5. Deborah Doroshow1,
  6. Natalie Lucas1,
  7. Kathy Wu1,
  8. Olivia Hapanowicz1,
  9. Paula King1,
  10. Pauline Hamon1,
  11. Jessica Le Berichel1,
  12. Diane Del Valle1,
  13. Clotilde Hennequin1,
  14. Seunghee Kim-Schulze1,
  15. Sacha Gnjatic1,
  16. Miriam Merad1,
  17. Zhen Zhao1,
  18. Stephen Ward1,
  19. Maria Isabel Fiel1,
  20. Mary Beasley1,
  21. Edward Kim1,
  22. Kirema Garcia-Reyes1,
  23. Udit Chaddha1,
  24. Timothy Harkin1,
  25. David Yankelevitz1,
  26. Ganesh Gunasekaran1,
  27. Parissa Tabrizian1,
  28. Myron Schwartz1,
  29. Andrew Kaufman1,
  30. Daniel Nicastri1,
  31. Andrew Wolf1 and
  32. Raja Flores1
  1. 1Icahn School of Medicine at Mount Sinai, New York, NY, USA
  2. 2Centro Nacional de Investigaciones Oncológicas, Madrid, Spain


Background Immune checkpoint blockade (ICB) has revolutionized cancer treatment; however, most patients fail to achieve the full clinical benefit of ICB. Although anti-PD-1 agents are FDA-approved for non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC), only a minority of patients respond clinically.1,2 This limited response is likely due, in part, to immunosuppressive factors within the tumor microenvironment (TME). Myeloid cells, specifically monocyte-derived macrophages (mo-Macs) and immature granulocytes (iPMNs), make up the majority of leukocytes in the TME and suppress anti-tumor immunity; pre-clinical work has revealed that tumor-derived CCR2 ligands and interleukin-8 (IL-8) play a key role in recruiting mo-Macs and iPMNs, respectively, to the TME.3-7 Disrupting these signaling pathways appears to potentiate the role of PD-1 blockade in mouse models, although only modest clinical benefit has been demonstrated to date in metastatic cancer models. In this “window-of-opportunity” trial, patients will receive neoadjuvant nivolumab monotherapy or neoadjuvant nivolumab in conjunction with a CCR2/5 inhibitor or an anti-IL8 antibody prior to surgical resection, providing a unique opportunity to elaborate the specific effects of these agents on the TME and to identify factors that may allow clinicians to better predict response in the future.

Methods This phase IIa multi-cohort, two-stage trial was designed to assess the clinical efficacy of BMS-813160 (CCR2/5 inhibitor) and BMS-986253 (anti-IL8 antibody) in patients with resectable NSCLC and HCC. The trial contains 2 cohorts (NSCLC and HCC) consisting of 5 arms (figure 1); arms A and B will enroll patients with NSCLC and arms C, D, and E will enroll patients with HCC. Patients will be treated with neoadjuvant nivolumab either alone (arm C) or in combination with BMS-813160 (arms A and D) or BMS-986253 (arms B and E). The patients will then undergo surgical resection, followed by standard-of-care adjuvant therapy in the NSCLC cohort or adjuvant nivolumab therapy in the HCC cohort. The primary endpoint for the NSCLC cohort is major pathologic response, defined as ≤10% viable tumor at time of surgery. The primary endpoint for the HCC cohort is significant tumor necrosis, defined as >70% tumor necrosis at time of surgery. The secondary endpoints are time to surgery, safety and tolerability, radiographic response, progression-free survival, and overall survival. Tissue, blood, and stool will be collected prior to treatment and at the time of surgery. Deep immune monitoring will be performed using multiplex and single-cell analysis platforms to define the immunodynamic effects of the therapies.

Trial Registration NCT04123379


  1. Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. New England Journal of Medicine. 2018;378(21):1976–86.

  2. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (Checkmate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. The Lancet. 2017;389(10088):2492–502.

  3. Casanova-Acebes M, Dalla E, Leader AM, LeBerichel J, Nikolic J, Morales BM, et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. Nature. 2021;595(7868):578–84.

  4. Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, et al. Monocytic CCR2+ myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Research. 2012;72(4):876–86.

  5. Schlecker E, Stojanovic A, Eisen C, Quack C, Falk CS, Umansky V, et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. The Journal of Immunology. 2012;189(12):5602–11.

  6. Hegde S, Leader AM, Merad M. MDSC: Markers, development, states, and unaddressed complexity. Immunity. 2021;54(5):875–84.

  7. Teijeira Á, Garasa S, Gato M, Alfaro C, Migueliz I, Cirella A, et al. CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity. Immunity. 2020;52(5).

Ethics Approval This trial obtained approval from the Icahn School of Medicine at Mount Sinai Institutional Review Board (#18-2375); all patients gave informed consent before participating in this trial.

Abstract 629 Figure 1

: Trial Schema

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.